Progressive multifocal leukoencephalopathy (PML) is a rare but serious brain infection. It gradually destroys brain tissue and often leads to death within a few weeks. It is triggered by human ...

Please provide your email address to receive an email when new articles are posted on . Use of a genetic risk test for patients considering immunosuppressive therapies associated with development of ...

Progressive multifocal leukoencephalopathy (PML), caused by reactivation of JC virus, typically develops in individuals with profound immunosuppression, but may also occur in those with more subtle ...

Progressive multifocal leukoencephalopathy (PML) is a rare but serious brain infection. It gradually destroys brain tissue and often leads to death within a few weeks. It is triggered by human ...

New research has confirmed a strong link between four genetic mutations and progressive multifocal leukoencephalopathy (PML), a rare but often fatal brain infection that can be triggered by dozens of ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...

Kamble et al. 1 recently provided a review of cases of central nervous system graft-versus-host disease (CNS GVHD). The authors conclude that ‘when relapse of a CNS neoplastic process, opportunistic ...

A new study found dozens of FDA approved drugs can increase the risk of developing progressive multifocal leukoencephalopathy, a rare and often fatal brain infection, by an average of eight times. The ...

Progressive multifocal leukoencephalopathy (PML) occurring with ocrelizumab (Ocrevus) monotherapy developed in a 78-year-old man with progressive multiple sclerosis (MS), the first such case known, ...

ROCKVILLE, Md.--(BUSINESS WIRE)--NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced that the first patient has been dosed in the pilot ...